Overview
Sponsor-declared trial summary
Phase
Human pharmacology (Phase I) - Other
Status
Ongoing, recruiting
Participants planned
40
Countries
1
Sites
1
Not applicable for phase I study
Key facts
- Sponsor
- Antabio
- Participant type
- Healthy volunteers
- Age range
- 18-64 years
- Gender
- Male and Female
- Therapeutic area
- Not possible to specify
- Trial duration
- 15 Jun 2026 → ongoing
- Decision date (initial)
- 2026-06-12
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- Yes
Trial design
CTIS Part I — objectives, methods, condition coding
Conditions and MedDRA coding
Not applicable for phase I study
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Antabio
- Sponsor organisation
- Antabio
- Address
- Biostep, 436 Rue Pierre Et Marie Curie 436 Rue Pierre Et Marie Curie
- City
- Labege
- Postcode
- 31670
- Country
- France
Scientific contact point
- Organisation
- Antabio
- Contact name
- Christian Zwingelstein
Public contact point
- Organisation
- Antabio
- Contact name
- Carine Danaire
Locations
1 EU/EEA country · 1 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| France | Ongoing, recruiting | 40 | 1 |
| Rest of world | — | 0 | — |
Investigational sites
Country notifications
Trial-start, recruitment-start, end and early-termination notifications submitted per Member State
| Country | Trial start | Trial end | Recruitment start | Recruitment end | Early termination |
|---|---|---|---|---|---|
| France | 2026-06-15 | 2026-06-17 |
Application history
1 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2026-04-27 | France | Acceptable with conditions 2026-06-12
|
2026-06-12 |